Fundraising Fox
Taxis Pharmaceuticals
Monmouth, US · Delaware corporation
Find your way into Taxis Pharmaceuticals
Sign up to see every warm intro you have to Taxis Pharmaceuticals
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Taxis Pharmaceuticals team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
TAXIS Pharmaceuticals is a biotech company developing novel anti-resistance agents targeting bacterial cell wall mechanisms to combat antimicrobial resistance across infectious diseases. The company serves healthcare providers, pharmaceutical partners, and patients affected by antibiotic-resistant infections.
Founders & leadership
DP
Daniel PilchNamed on SEC filing
Board
EM
Ernest MarioChairman
Reported raises · per SEC filings
Form D private placements$5.3M disclosed across 3 of 4 rounds · 2016–2018
▶$1.1MraisedJan 2019 · 7 investors · PharmaceuticalsRule 506(b)
▶$1.1MraisedJan 2019 · 7 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Edmond J. LaVoieDirector
- David S. KimballDirector
- Ernest MarioDirector
- Gregory G. MarioExecutive Officer, Director
- Christopher M. CimarustiDirector
- Offering amount
- $5M
- Amount sold
- $1.1M
- Minimum investment
- $25K
- First sale
- Dec 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$5MofferedSep 2017 · PharmaceuticalsRule 506(b)
▶$5MofferedSep 2017 · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Gail McIntyreDirector
- Gregory G. MarioExecutive Officer, Director
- David KimballDirector
- Ernest MarioDirector
- Edmond LaVoieDirector
- Offering amount
- $5M
- Minimum investment
- $50K
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1.2MraisedMar 2017 · 14 investors · PharmaceuticalsRule 506(b)
▶$1.2MraisedMar 2017 · 14 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- David KimballDirector
- Ernest MarioDirector
- Greg MarioExecutive Officer, Director
- Gail McIntyreDirector
- Edmond LaVoieDirector
- Offering amount
- $1.8M
- Amount sold
- $1.2M
- Minimum investment
- $25K
- First sale
- Feb 2017
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$3MraisedJun 2016 · 33 investors · PharmaceuticalsRule 506(b)
▶$3MraisedJun 2016 · 33 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Edmond LaVoieDirector
- Ernest MarioDirector
- Greg MarioExecutive Officer, Director
- Daniel PilchDirector
- Offering amount
- $4.8M
- Amount sold
- $3M
- Minimum investment
- $5K
- First sale
- May 2016
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does Taxis Pharmaceuticals do?
- TAXIS Pharmaceuticals is a biotech company developing novel anti-resistance agents targeting bacterial cell wall mechanisms to combat antimicrobial resistance across infectious diseases. The company serves healthcare providers, pharmaceutical partners, and patients affected by antibiotic-resistant infections.
- Who founded Taxis Pharmaceuticals?
- Taxis Pharmaceuticals was founded by Edmond LaVoie.
- How much funding has Taxis Pharmaceuticals raised?
- Taxis Pharmaceuticals has disclosed $5.3M raised across 3 of its 4 known rounds.
- Where is Taxis Pharmaceuticals headquartered?
- Taxis Pharmaceuticals is headquartered in Monmouth, US.